Virios Therapeutics Inc is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia. The company is engaged in the development of its product, IMC-1, for people wh... Virios Therapeutics Inc is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia. The company is engaged in the development of its product, IMC-1, for people who are suffering from fibromyalgia. Show more
Strategic financing by an affiliate of CK Life Sciences Int’l., (Holdings) Inc., results in working capital of approximately $23 million to fund operations and advance Phase 2b Halneuron®...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 3.875 | 3.875 | 3.875 | 0 | 0 | CS |
4 | 0 | 0 | 3.875 | 3.875 | 3.875 | 0 | 0 | CS |
12 | -0.675 | -14.8351648352 | 4.55 | 5.705 | 3.15 | 911301 | 3.94655695 | CS |
26 | -1.6325 | -29.6413980935 | 5.5075 | 9.395 | 3.15 | 1208666 | 5.13753946 | CS |
52 | -10.3 | -72.6631393298 | 14.175 | 23.5 | 3.15 | 814933 | 6.21291137 | CS |
156 | -122.875 | -96.942800789 | 126.75 | 227.7725 | 3.15 | 709301 | 17.09882208 | CS |
260 | -340.125 | -98.8735465116 | 344 | 359.75 | 3.15 | 577121 | 29.01959287 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales